Anteris Technologies (ASX:AVR) completed its initial public offering in the US, issuing 14.8 million shares at $6 each to raise gross proceeds of $88.8 million, according to a Tuesday filing with the Australian bourse.
The company's stock started trading on the Nasdaq Global Market under the ticker "AVR" on Dec. 13, the filing said.
The company will also list its Chess Depositary Interests on the Australian stock exchange under the ticker "AVR," the filing added.
The company plans to use the proceeds from the IPO to fund the development of its DurAVR transcatheter heart valve and a global clinical study for the valve to treat aortic stenosis, with remaining funds for working capital and debt repayment.
Shares of the company fell nearly 15% in recent Tuesday trade.
Price (AUD): $9.00, Change: $-1.54, Percent Change: -14.61%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.